MDACC Study No:2011-0164 ( NCT No: NCT01328626)
Title:A Phase 1 Study Evaluating the Safety and
Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory
Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Principal Investigator:William G. Wierda
Treatment Agent:ABT-199
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of ABT-199 that can be given patients with relapsed or refractory CLL, NHL, or
SLL. The safety of this drug will also be studied.

ABT-199 is designed to block a critical protein that the leukemia cells need to
survive, which may kill cancer cells and shrink tumors. This is the first study
using ABT-199 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:ABT-199
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Abbott
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults